Trial Profile
A clinical trial of N-115 (Non-Steroidal Nasal Spray) for the treatment of COVID-19
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2020
At a glance
- Drugs Sodium pyruvate (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 24 Mar 2020 New trial record
- 17 Mar 2020 According to an EmphyCorp media release, N115 Non-Steroidal Nasal Spray is currently being tested in clinical trials as a potential treatment for patients infected with the Coronavirus.
Most Recent Events
Trial Overview
Purpose
This trial will assess N-115 (Non-Steroidal Nasal Spray) for the treatment of COVID-19.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| Sodium pyruvatePrimary Drug | Inhalation |
-
|
N-115 (Non-Steroidal Nasal Spray)
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 24 Mar 2020 | New trial record | New trial record Updated 24 Mar 2020 |
| 17 Mar 2020 | Other trial event | According to an EmphyCorp media release, N115 Non-Steroidal Nasal Spray is currently being tested in clinical trials as a potential treatment for patients infected with the Coronavirus. Updated 24 Mar 2020 |
References
-
Emphycorp. EmphyCorp News: Nitric Oxide is currently being tested in Clinical Trials as a Potential Treatment for Patients infected with the Coronavirus. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG